Leonard Post Biography and Net Worth

Director of uniQure

Leonard Post has over 35 years of experience in the pharmaceutical industry, where he has held various global executive positions and has extensive experience in the research and development of product candidates. From 2016 to January 2024, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules targeting the hippo pathway and, from 2018 to January 2024, as Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology. From February 2010 until June 2016, Dr. Post worked at BioMarin (Nasdaq: BMRN), in various positions including Chief Scientific Officer. During that time, he oversaw the initiation of BioMarin’s first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners. Dr. Post is a virologist by training and did early work on the engineering of the herpes simplex virus as a post-doctoral fellow. He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin.

What is Leonard E. Post's net worth?: The estimated net worth of Leonard E. Post is at least $673.79 thousand as of June 20th, 2025. Mr. Post owns 29,937 shares of uniQure stock worth more than $673,792 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Post may own. Learn More about Leonard E. Post's net worth.
How do I contact Leonard E. Post?: The corporate mailing address for Mr. Post and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Leonard E. Post's contact information.
Has Leonard E. Post been buying or selling shares of uniQure?: Leonard E. Post has not been actively trading shares of uniQure during the last ninety days. Most recently, Leonard E. Post sold 2,112 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a transaction totalling $30,518.40. Following the completion of the sale, the director now directly owns 29,937 shares of the company's stock, valued at $432,589.65. Learn More on Leonard E. Post's trading history.
Who are uniQure's active insiders?: uniQure's insider roster includes Walid Abi-Saab (Insider), Madhavan Balachandran (Director), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Jack Kaye (Director), Christian Klemt (CFO), Alexander Kuta, III (VP), David Meek (Director), Leonard Post (Director), and Jeannette Potts (Insider). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?: In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 432,748 shares worth more than $13,686,033.43. The most recent insider tranaction occured on November, 6th when Director Robert Gut sold 31,434 shares worth more than $856,890.84. Insiders at uniQure own 4.8% of the company. Learn More about insider trades at uniQure.
Information on this page was last updated on 11/6/2025.

Leonard E. Post Insider Trading History at uniQure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/20/2025	Sell	2,112	$14.45	$30,518.40	29,937
2/28/2022	Sell	795	$16.64	$13,228.80

Leonard E. Post Buying and Selling Activity at uniQure

uniQure Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Today's Range

Now: $22.74

$21.00

$23.98

50 Day Range

MA: $45.23

$22.74

$70.59

2 Week Range

Now: $22.74

$6.14

$71.50

Volume

9,092,137 shs

Average Volume

2,488,021 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59